Timing note: GE HealthCare is scheduled to report today, Wednesday, July 29, 2026, before the market opens, with its earnings call at 8:30 a.m. ET—not tomorrow. (investor.gehealthcare.com)
This is no longer a conventional earnings event: GE HealthCare already preannounced the quarter’s principal headline figures on July 23. The company expects:
The preliminary results are encouraging, particularly because management had previously expected second-quarter adjusted EPS to decline at a low-single-digit rate. Adjusted EPS exceeded $1.06, the year-ago result, although GEHC has not disclosed the exact figure. (investor.gehealthcare.com)
Consequently, the market’s focus should shift from whether GEHC met the quarter to how it produced the earnings upside and whether the second-half margin assumptions embedded in guidance remain credible.
| Metric | Preliminary 2Q26 result | 2Q25 comparison | Initial read |
|---|---|---|---|
| Revenue | ~$5.295B | $5.007B | Solid reported growth |
| Reported growth | 5.7% | 3% in 2Q25 | Includes FX and acquisitions |
| Organic growth | 3.5% | 2% in 2Q25 | Within initial 3%–4% expectation |
| Adjusted EPS | Above $1.06 | $1.06 | Better than management’s prior expectation |
| FY26 outlook | Reaffirmed | — | Positive, but execution remains back-half weighted |
The quarter’s 3.5% organic growth follows 2.9% in the first quarter, putting first-half organic growth at approximately 3.2%. That is consistent with the lower-to-middle portion of the full-year range, but reaching the upper half of guidance will require stronger growth in the second half. (investor.gehealthcare.com)
Revenue has been substantially de-risked. The most consequential number will therefore be adjusted EBIT margin.
First-quarter adjusted EBIT margin fell 150 basis points to 13.5%, reflecting tariffs, weakness in Patient Care Solutions and a Pharmaceutical Diagnostics supplier issue. GEHC nevertheless reaffirmed a full-year adjusted EBIT margin target of 15.4%–15.7%, representing 10–40 basis points of annual expansion. (investor.gehealthcare.com)
That target implies a pronounced second-half improvement. Investors should focus on:
A revenue-and-EPS beat generated through sustainable pricing, better volume and supplier normalization would be substantially more valuable than one driven by favorable taxes, timing or non-operating items.
Current 2026 guidance is:
| Metric | FY26 guidance |
|---|---|
| Organic revenue growth | 3.0%–4.0% |
| Adjusted EBIT margin | 15.4%–15.7% |
| Adjusted EPS | $4.80–$5.00 |
| Adjusted tax rate | 20%–21% |
| Free cash flow | Approximately $1.6B |
GEHC reduced its profit outlook in April because of approximately $250 million of expected incremental inflation, principally memory chips, oil and freight. Management expected to offset more than half of that pressure through pricing and cost measures, with a greater benefit in the second half and into 2027. (investor.gehealthcare.com)
The July 23 reaffirmation is reassuring, but the call needs to establish whether management now sees:
Following Q1 adjusted EPS of $0.99 and Q2 adjusted EPS above $1.06, GEHC has earned more than $2.05 through the first half. Reaching the $4.90 midpoint still requires roughly $2.85 or less—but close to that level—during the second half, underscoring the importance of the expected margin step-up.
GEHC is combining Imaging and Advanced Visualization Solutions into Advanced Imaging Solutions, so this quarter will introduce a new three-segment reporting structure.
In Q1, legacy Imaging organic revenue grew 3.8% while AVS grew 4.4%. The combined business benefits from healthy capital-equipment demand, service revenue and new-product adoption, but Q2 orders and book-to-bill will be more informative than reported revenue.
Key questions:
Photonova Spectra photon-counting CT is unlikely to contribute meaningful revenue until 2027, but orders, customer-site preparation and the size of the commercial funnel could influence confidence in next year’s growth acceleration. (investor.gehealthcare.com)
PCS was Q1’s clearest operating weakness:
The bull case assumes those installations convert as scheduled, backlog execution improves and the planned premium anesthesia launch supports orders later in the year. Investors should look for at least sequential stabilization and confirmation that the delayed projects remain on track.
Another weak order or margin result would make the full-year consolidated margin target more difficult to achieve.
PDx delivered 9.7% organic growth in Q1 but suffered a 680-basis-point segment margin contraction, partly because of the supplier issue that management said had been resolved. (investor.gehealthcare.com)
Q2 should therefore answer two questions:
Flyrcado was running at roughly a $46 million annualized revenue rate in April, and GEHC continues to target at least $500 million of annual revenue by 2028. Updates on weekly doses, customer additions, production reliability and reimbursement will be important leading indicators.
GEHC’s preliminary release cited “strong orders” and healthy end-market demand, but provided no numbers. (investor.gehealthcare.com)
Given that revenue and EPS have already been directionally disclosed, order data could be the biggest source of incremental information:
Particular attention should go to capital equipment demand in China and the timing of large PCS projects.
CFO Jay Saccaro is leaving for a role outside the medical-technology industry and will remain through August 14. Controller and Chief Accounting Officer George Newcomb has been appointed interim CFO while GEHC searches for a permanent successor. (investor.gehealthcare.com)
The simultaneous preliminary-results announcement helps reduce concern that the departure was caused by an imminent financial shortfall. Nonetheless, investors should expect questions about:
A smooth, detailed handover message would limit the issue. Vague responses could overshadow otherwise solid results.
| Outcome | What it would likely include |
|---|---|
| Positive | Adjusted EPS meaningfully above $1.06; strong operating margin; healthy orders and book-to-bill; PDx margin recovery; PCS stabilization; increased confidence in the upper half of FY guidance |
| Neutral | Results close to the preliminary figures; modest EPS growth; guidance reiterated without greater confidence; continued dependence on Q3–Q4 pricing and productivity |
| Negative | EPS upside driven by tax or adjustments; weak orders; limited PCS improvement; persistent PDx margin pressure; renewed China weakness; management signaling the low end of FY guidance |
The preliminary release makes a headline miss unlikely. The real earnings test is whether GEHC can demonstrate that the Q2 EPS upside came from improving operations and that its second-half margin ramp is achievable.
The most important items, in order, are:
A quarter with strong orders, operating-driven EPS growth and a credible margin bridge could begin rebuilding confidence after Q1’s guidance reduction. Conversely, a simple guidance reiteration without stronger evidence behind the second-half assumptions may not be enough.